DGAP-News: Aladdin Healthcare Technologies SE achieves further milestone in COVID-19 drug development: Discovery of 20 new optimized compounds with AI DD platform
DGAP-News: Aladdin Healthcare Technologies SE
/ Key word(s): Miscellaneous
Aladdin Healthcare Technologies SE achieves further milestone in COVID-19 drug development: Discovery of 20 new optimized compounds with AI DD platform The Company has concluded a partnership with the Sun-Yat Sen University in China, a leading university for Medicine, in order to develop new optimized compounds to combat coronavirus pandemic. Starting from experimental data about Remdesivir, a broad-spectrum antiviral medicament already tested as a treatment for COVID-19, Aladdin was able to discover more than 20 new synthesisable compounds for drug development analogous to the original medicinal but with a better binding affinity and an unharmful grade of liver toxicity, which is actually the major concern of some existing repurposed drug candidates. Aladdin's AI platform, by using key innovative components such as the virtual screening technology and molecule design based on Artificial Intelligence (AI), speeds up the drug discovery process and enables the optimization of new drug compounds. The platform acts like a huge dynamic database, which is continuously kept updated with new data provided by all partners and clients whom Aladdin works with. In this way, the groundbreaking Big Data technology connects findings and dynamizes the knowledge progress for the treatment of diseases such as COVID-19 but also age-related diseases. Wade Menpes-Smith, CEO of Aladdin Healthcare Technologies SE, says: "Our proprietary AI drug discovery platform can primarily accelerate the discovery of novel molecules for drug targets to combat complex diseases and viruses like the SARS-CoV-2. Our primary aim is to be a major player in the science progress by combining data science with Artificial Intelligence." Aladdin works with numerous renowned partners such as pharma and biotech companies, labs and universities in Europe and Asia, providing them with an expert consulting service and allowing them to use its proprietary AI powered platform on payment of a fee. By doing that, Aladdin is able to conduct major projects and to find early stage drug targets which the Company get paid for, after the pre-clinical validation. Most recently, Aladdin and its partners received EU funding of EUR 1.4 million for the development of COVID-19 diagnostic components. Keeping making new discoveries through numerous partnerships will lead Aladdin to further major contracts. About Aladdin Healthcare Technologies SE Website Link: www.aladdinid.com For further information Contact Press
20.05.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
Language: | English |
Company: | Aladdin Healthcare Technologies SE |
Unter den Linden 10 | |
10117 Berlin | |
Germany | |
Phone: | 030 700140449 |
E-mail: | [email protected] |
Internet: | www.aladdinid.com |
ISIN: | DE000A12ULL2 |
WKN: | A12ULL |
Listed: | Regulated Market in Dusseldorf |
EQS News ID: | 1051457 |
End of News | DGAP News Service |
|
1051457 20.05.2020